102
Participants
Start Date
July 1, 2019
Primary Completion Date
September 21, 2022
Study Completion Date
May 26, 2023
inotuzumab ozogamicin-dose level 2
Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle. This treatment arm evaluates a lower starting dose of 1.2mg/m2/cycle.
Inotuzumab ozogamicin-dose level 1
Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose of 1.8mg/m2/cycle is administered in this treatment arm.
Changhua Christian Hospital, Changhua
Debreceni Egyetem Klinikai Központ, Orvosi Kepalkotó Klinika, Radiológia, Debrecen
Debreceni Egyetem Klinikai Központ, Pathológiai lntézet, Debrecen
Szabolcs-Szatmar Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Korhaz, Hematologia, Nyíregyháza
National Taiwan University Hospital, Taipei
University of Maryland- Greenebaum Comprehensive Cancer Center, Baltimore
Hospital General Universitario Gregorio Maranon, Madrid
Hospital Universitario Ramon y Cajal, Madrid
Hospital Universitario Central de Asturias, Oviedo
Marmara University Pendik Training and Research Hospital Hematology Unit, Istanbul
Ege University Medical Faculty, Izmir
Dokuz Eylul University Medical Faculty, Izmir
Medicalpark Izmir Hospital, Izmir
Erciyes Universitesi Tip Fakultesi Hastaneleri, Kayseri
Hospital General - Semisótano, Seville
Hospital Universitario Virgen del Rocio, Seville
Anadolu Health Center Hospital, Gebze
Hospital Clinico Universitario de Valencia, Valencia
Hospital Universitari i Politecnic La Fe, Valencia
Ondokuz Mayis University Faculty Of Medicine Hospital, Samsun
Rush University Medical Center, Chicago
Keck Hospital of USC, Los Angeles
LAC+USC Medical Center, Los Angeles
USC/Norris Comprehensive Cancer Center, Los Angeles
University of Washington Medical Center, Seattle
National University Hospital, Singapore
Artemis hospital, Gurugram
Raffles Hospital, Singapore
Raffles Radiology, Singapore
Sahyadri Clinical Research and Development Centre, Pune
Sahyadri Super Speciality Hospital, Pune
Sahyadri Super Speciality Hospital Nagar Road, Pune
Sahyadri Super Speciality Hospital, Pune
Christian Medical College, Vellore
Christian Medical College Vellore- Ranipet Campus, Ranipet - 632517, Tamil Nadu, India
Seattle Cancer Care Alliance, Seattle
Klinika Hematologii i Transplantologii, Uniwersyteckie Centrum Kliniczne, Gdansk
Instytut Hematologii i Transfuzjologii, Warsaw
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza - Radeckiego we Wroclawiu, Wroclaw
Apteka Centralna, Wroclaw
Hospital Universitari Vall d'Hebron, Barcelona
Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Clinical Research Center, Ankara
Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Hematology Department, Ankara
Ankara University Faculty of Medicine Cebeci Hospital Hematology Department, Ankara
Private Medstar Antalya Hosp. Hematology and Stem Cell Transplantation Center, Antalya
Lead Sponsor
Pfizer
INDUSTRY